Elutia Inc (ELUT) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Product Growth ... [Yahoo! Finance]
Elutia, Inc. - Class A (ELUT)
Company Research
Source: Yahoo! Finance
Full Year BioEnvelope Sales: $9.9 million, reflecting a 5% growth year-over-year. SimpliDerm Sales: $2.3 million for the quarter, down year-over-year; $11.6 million for the full year, up 12% year-over-year. Cardiovascular Sales: $0.5 million for the quarter, compared to $600,000 in the prior year quarter. Total Revenue: $5.5 million for the quarter, down 7% year-over-year; $24.4 million for the full year, down 1% from the prior year. Gross Margin: 43% for the quarter, up from 36% in the prior year; 58% excluding non-cash amortization, up from 51% in the prior year. Operating Expenses: $10.8 million for the quarter, consistent with $10.6 million in the prior year. Loss from Operations: $8.4 million for the quarter, compared to $8.5 million in the prior year. Adjusted EBITDA: Loss of $3.8 million for the quarter, improved from a $4.5 million loss in the prior year. Cash Position: $13.2 million at the end of the quarter. Post-Quarter Cash Raise: $15 million raised in g
Show less
Read more
Impact Snapshot
Event Time:
ELUT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELUT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELUT alerts
High impacting Elutia, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ELUT
News
- Elutia (NASDAQ:ELUT) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ELUT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> to MarketBeat
- Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x DevelopmentGlobeNewswire
- Elutia (NASDAQ:ELUT) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025GlobeNewswire
- Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21GlobeNewswire
ELUT
Sec Filings
- 12/15/25 - Form 4
- 12/15/25 - Form SCHEDULE
- 12/12/25 - Form 4
- ELUT's page on the SEC website